Metastasectomy for abdominal visceral oligometastatic melanoma
Menée à partir de données portant sur 1 623 patients présentant des métastases abdominales ayant pour origine un mélanome diagnostiqué entre 1965 et 2014 (âge moyen : 54,6 ans ; proportion d'hommes : 67,6 %), cette étude évalue le bénéfice, en termes de survie globale, d'une métastasectomie par rapport à une chimiothérapie systémique moderne
In the era of targeted immunotherapy for stage IV melanoma, there is general agreement that patients with isolated abdominal metastases should be treated with resection if they can be rendered no evidence of disease. Similarly, there is little debate that patients with substantial disease burden should be offered palliative metastasectomy only in cases of bleeding, obstruction, or pain to address their symptoms.1 We agree with the conclusion of Deutsch et al2 supporting the importance of surgical resection in selected patients with abdominal metastases from melanoma and congratulate the authors on compiling their institutional experience with an impressive number of patients and long-term follow-up.2
JAMA Surgery , commentaire, 2016